Distinguished in Malignant Mixed Mullerian Tumor

Dr. Karim S. Elsahwi

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Hackensack Meridian Health Medical Group - Specialty Care PC
1945 Route 33, 
Neptune, NJ 
Distinguished in Malignant Mixed Mullerian Tumor
Hackensack Meridian Health Medical Group - Specialty Care PC
1945 Route 33, 
Neptune, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karim Elsahwi is a Gynecologic Oncologist and an Oncologist in Neptune, New Jersey. Dr. Elsahwi is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Cancer, Hysterectomy, and Oophorectomy.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NJ
Hospital Affiliations
Ocean Medical Center
Riverview Medical Center
Southern Ocean Medical Center
Jfk University Medical Center
Jersey Shore University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
1945 Route 33, Neptune, NJ 07753
Other Locations
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
30 Prospect Ave, Suite 2, Hackensack, NJ 07601
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
3600 Route 66, Fl 3, Neptune, NJ 07753
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
425 Jack Martin Blvd, Fl 2, Brick, NJ 08724
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
1610 Route 88, Brick, NJ 08724
HACKENSACK MERIDIAN HEALTH MEDICAL GROUP - SPECIALTY CARE PC
1 Riverview Plz, Red Bank, NJ 07701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 6 Less Clinical Trials

17 Total Publications

Bilateral malignant struma ovarii with concurrent thyroid carcinoma.
Bilateral malignant struma ovarii with concurrent thyroid carcinoma.
Journal: BMJ case reports
Published: April 08, 2025
Similar Doctors
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Thomas E. Hackett
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Thomas E. Hackett
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Barnabas Health Medical Group PC

99 Hwy 37 W, 
Toms River, NJ 
 (19.2 miles away)
732-477-8988
Languages Spoken:
English
See accepted insurances

Thomas Hackett is a Gynecologic Oncologist and an Oncologist in Toms River, New Jersey. Dr. Hackett is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Oophorectomy, and Salpingo-Oophorectomy.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. David P. Warshal
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. David P. Warshal
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Redeemer Cancer Care Physicians Network, LLC

1648 Huntingdon Pike, 
Meadowbrook, PA 
 (56.0 miles away)
215-938-3555
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Warshal is a Gynecologic Oncologist and an Oncologist in Meadowbrook, Pennsylvania. Dr. Warshal is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Lymphadenectomy. Dr. Warshal is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Nana E. Tchabo
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Nana E. Tchabo
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Practice Associates Medical Group

11 Overlook Rd, 
Summit, NJ 
 (38.6 miles away)
908-273-1493
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Nana Tchabo is a Gynecologic Oncologist and an Oncologist in Summit, New Jersey. Dr. Tchabo is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. Her top areas of expertise are Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy. Dr. Tchabo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Elsahwi's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile